Loading...
BMY logo

Bristol-Myers Squibb CompanyNYSE:BMY Stock Report

Market Cap US$89.2b
Share Price
US$43.83
My Fair Value
US$53
17.3% undervalued intrinsic discount
1Y-15.6%
7D0.5%
Portfolio Value
​
View

Bristol-Myers Squibb Company

NYSE:BMY Stock Report

Market Cap: US$89.2b

Bristol-Myers Squibb (BMY) Stock Overview

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. More details

BMY fundamental analysis
Snowflake Score
Valuation4/6
Future Growth2/6
Past Performance2/6
Financial Health3/6
Dividends5/6

Rewards

Trading at 66.9% below our estimate of its fair value

Earnings are forecast to grow 5.76% per year

Became profitable this year

Risk Analysis

Has a high level of debt

Dividend of 5.66% is not well covered by earnings

Large one-off items impacting financial results


BMY Community Fair Values

Create Narrative

See what 301 others think this stock is worth. Follow their fair value or set your own to get alerts.

BMY logo
Bristol-Myers Squibb

Aging Demographics And Genomics Will Drive Healthcare Demand

Key Takeaways An expanding pipeline, strategic partnerships, and strong global launches are driving growth and offsetting competition and patent challenges. Operational streamlining and investment in high-value clinical programs support margin improvement and long-term financial stability.
View narrative
US$53
FV
17.3% undervalued intrinsic discount
-4.72%
Revenue growth p.a.
1users have liked this narrative
0users have commented on this narrative
189users have followed this narrative
BMY logo
Bristol-Myers Squibb

Debt And Patent Expiries Will Erode US Pharma Margins

Key Takeaways Loss of exclusivity and pricing pressures will erode revenue and margin growth, posing significant long-term financial headwinds. High debt, execution risk, and tougher regulatory climate restrict flexibility, increase costs, and threaten sustainable profitability.
View narrative
US$35.86
FV
22.2% overvalued intrinsic discount
-6.36%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
5users have followed this narrative
BMY logo
Bristol-Myers Squibb

Bristol Myers Squibb (BMY): Undervalued Opportunity or Value Trap? A Deep Dive into 2024 Earnings and Fair Value

Fourth Quarter 2024 Highlights: Total Revenues: $12.3 billion, an 8% increase from the same period in 2023. GAAP Earnings Per Share (EPS): $0.04, a significant decrease from $0.87 in Q4 2023.
View narrative
US$65
FV
32.6% undervalued intrinsic discount
2.43%
Revenue growth p.a.
3users have liked this narrative
0users have commented on this narrative
15users have followed this narrative
BMY logo
Bristol-Myers Squibb

Pipeline Launches And Global Healthcare Trends Will Unlock Growth

Key Takeaways Robust portfolio performance and pipeline innovation, especially in immuno-oncology, are fueling faster-than-expected revenue growth and international market expansion. Strong cost discipline, operational efficiencies, and AI-driven R&D enhancements are creating substantial upside for margins and long-term earnings growth.
View narrative
US$68
FV
35.5% undervalued intrinsic discount
-3.14%
Revenue growth p.a.
0users have liked this narrative
0users have commented on this narrative
2users have followed this narrative
View Stock Community

Bristol-Myers Squibb Company Competitors

Price History & Performance

Summary of share price highs, lows and changes for Bristol-Myers Squibb
Historical stock prices
Current Share PriceUS$43.83
52 Week HighUS$63.33
52 Week LowUS$42.96
Beta0.34
1 Month Change-0.66%
3 Month Change-7.75%
1 Year Change-15.58%
3 Year Change-42.95%
5 Year Change-25.01%
Change since IPO1,951.28%

Recent News & Updates

The Play On Bristol-Myers Squibb

Oct 21

Recent updates

The Play On Bristol-Myers Squibb

Oct 21

We Think Bristol-Myers Squibb's (NYSE:BMY) Robust Earnings Are Conservative

May 05
We Think Bristol-Myers Squibb's (NYSE:BMY) Robust Earnings Are Conservative

Bristol-Myers Squibb: Extraordinary Dividend And FCF Yields Ready For Recession

Apr 22

Bristol-Myers Squibb's Rally Is Well Deserved, Albeit Warranting A Downgrade To Hold

Mar 25

Bristol-Myers Squibb: Why I'm Still Bullish

Mar 18

Bristol Myers Squibb (BMY): Undervalued Opportunity or Value Trap? A Deep Dive into 2024 Earnings and Fair Value

Total Revenues: $12.3 billion, an 8% increase from the same period in 2023.

Bristol-Myers Squibb Stock: A Strong Buy Amid Oncology Success

Feb 21

Bristol-Myers Squibb: Solid Q4 Earnings, But Weak Guidance And Patent Concerns Drive The Stock Down

Feb 07

Bristol-Myers Squibb: Too Valuable Not To Hold This Pharma Gem, But Debt Challenges Remain

Jan 31

Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.62

Dec 29
Bristol-Myers Squibb (NYSE:BMY) Is Increasing Its Dividend To $0.62

Bristol-Myers Squibb Will Handle The Patent Cliff And Is Still Undervalued

Dec 20

Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year

Dec 15
Bristol-Myers Squibb (NYSE:BMY) Is Paying Out A Larger Dividend Than Last Year

Revenues Not Telling The Story For Bristol-Myers Squibb Company (NYSE:BMY)

Nov 27
Revenues Not Telling The Story For Bristol-Myers Squibb Company (NYSE:BMY)

5 Reasons Bristol-Myers Squibb Looks Good Now (Rating Upgrade)

Nov 25

Bristol-Myers Squibb Deserves Its Place Among Its Big Pharma Brethren

Oct 28

Bristol-Myers Squibb: A High-Yield Bargain With Growth On The Horizon

Oct 06

Bristol-Myers Squibb: Cobenfy Approval A Major Coup For The Dealmaker (Upgrade)

Sep 27

Shareholder Returns

BMYUS PharmaceuticalsUS Market
7D0.5%1.3%2.0%
1Y-15.6%-3.3%17.9%

Return vs Industry: BMY underperformed the US Pharmaceuticals industry which returned -3.3% over the past year.

Return vs Market: BMY underperformed the US Market which returned 17.9% over the past year.

Price Volatility

Is BMY's price volatile compared to industry and market?
BMY volatility
BMY Average Weekly Movement3.6%
Pharmaceuticals Industry Average Movement9.4%
Market Average Movement6.5%
10% most volatile stocks in US Market17.4%
10% least volatile stocks in US Market3.0%

Stable Share Price: BMY has not had significant price volatility in the past 3 months compared to the US market.

Volatility Over Time: BMY's weekly volatility (4%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
188734,100Chris Boernerwww.bms.com

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company’s products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Opdivo for various anti-cancer indications; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel to treat patients with Philadelphia chromosome-positive chronic myeloid leukemia.

Bristol-Myers Squibb Company Fundamentals Summary

How do Bristol-Myers Squibb's earnings and revenue compare to its market cap?
BMY fundamental statistics
Market capUS$89.21b
Earnings (TTM)US$5.05b
Revenue (TTM)US$47.70b
17.7x
P/E Ratio
1.9x
P/S Ratio

Is BMY overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
BMY income statement (TTM)
RevenueUS$47.70b
Cost of RevenueUS$12.44b
Gross ProfitUS$35.26b
Other ExpensesUS$30.21b
EarningsUS$5.05b

Last Reported Earnings

Jun 30, 2025

Next Earnings Date

Oct 30, 2025

Earnings per share (EPS)2.48
Gross Margin73.92%
Net Profit Margin10.58%
Debt/Equity Ratio281.6%

How did BMY perform over the long term?

See historical performance and comparison

Dividends

5.7%
Current Dividend Yield
99%
Payout Ratio

Does BMY pay a reliable dividends?

See BMY dividend history and benchmarks
When do you need to buy BMY by to receive an upcoming dividend?
Bristol-Myers Squibb dividend dates
Ex Dividend DateOct 03 2025
Dividend Pay DateNov 03 2025
Days until Ex dividend24 days
Days until Dividend pay date7 days

Does BMY pay a reliable dividends?

See BMY dividend history and benchmarks

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/10/26 20:14
End of Day Share Price 2025/10/24 00:00
Earnings2025/06/30
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Bristol-Myers Squibb Company is covered by 43 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
David ToungArgus Research Company
Charles ButlerBarclays
Luisa HectorBerenberg